EE200200277A - 4-karboksüamino-2-etüül-1,2,3,4-tetrahüdrokinoliini kristall kui CETP inhibiitor - Google Patents

4-karboksüamino-2-etüül-1,2,3,4-tetrahüdrokinoliini kristall kui CETP inhibiitor

Info

Publication number
EE200200277A
EE200200277A EEP200200277A EEP200200277A EE200200277A EE 200200277 A EE200200277 A EE 200200277A EE P200200277 A EEP200200277 A EE P200200277A EE P200200277 A EEP200200277 A EE P200200277A EE 200200277 A EE200200277 A EE 200200277A
Authority
EE
Estonia
Prior art keywords
carboxyamino
tetrahydroquinoline
ethyl
crystal
cetp inhibitor
Prior art date
Application number
EEP200200277A
Other languages
English (en)
Inventor
John Meldrum Allen Douglas
Anthony Appleton Troy
Robinson Brostrom Lyle
Lawrence Tickner Derek
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200200277A publication Critical patent/EE200200277A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
EEP200200277A 1999-11-30 2000-11-14 4-karboksüamino-2-etüül-1,2,3,4-tetrahüdrokinoliini kristall kui CETP inhibiitor EE200200277A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30
PCT/IB2000/001650 WO2001040190A1 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Publications (1)

Publication Number Publication Date
EE200200277A true EE200200277A (et) 2003-10-15

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200277A EE200200277A (et) 1999-11-30 2000-11-14 4-karboksüamino-2-etüül-1,2,3,4-tetrahüdrokinoliini kristall kui CETP inhibiitor

Country Status (28)

Country Link
EP (1) EP1246804A1 (et)
JP (1) JP2003515592A (et)
KR (1) KR20020058057A (et)
CN (1) CN1402711A (et)
AP (1) AP2002002531A0 (et)
AU (1) AU1048801A (et)
BG (1) BG106854A (et)
BR (1) BR0015836A (et)
CA (1) CA2392979A1 (et)
CO (1) CO5271716A1 (et)
EA (1) EA200200510A1 (et)
EC (1) ECSP003792A (et)
EE (1) EE200200277A (et)
GT (1) GT200000199A (et)
HU (1) HUP0203521A2 (et)
IL (1) IL149097A0 (et)
IS (1) IS6338A (et)
MA (1) MA26845A1 (et)
MX (1) MXPA02005354A (et)
NO (1) NO20022558D0 (et)
OA (1) OA12099A (et)
PA (1) PA8506301A1 (et)
PE (1) PE20010904A1 (et)
PL (1) PL355892A1 (et)
TN (1) TNSN00231A1 (et)
TR (1) TR200201446T2 (et)
UY (1) UY26454A1 (et)
WO (1) WO2001040190A1 (et)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
TNSN03139A1 (fr) 2001-06-21 2005-12-23 Pfizer Prod Inc Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle
GT200200170A (es) 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
KR100664822B1 (ko) * 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
ES2277142T3 (es) 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
AU2004222436A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
CN1795177A (zh) * 2003-03-28 2006-06-28 辉瑞产品公司 作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , －取代的1，2，3，4，－四氢－和1，2二氢－喹啉以及1， 2 , 3 ， 4－四氢－喹喔啉衍生物
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
PL1670768T3 (pl) 2003-10-08 2010-01-29 Lilly Co Eli Związki i sposoby leczenia dyslipidemii
US7737295B2 (en) * 2004-04-13 2010-06-15 Merck Sharp & Dohme Corp. CETP inhibitors
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
RU2703192C2 (ru) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
JP2003515592A (ja) 2003-05-07
GT200000199A (es) 2002-05-23
CO5271716A1 (es) 2003-04-30
IL149097A0 (en) 2002-11-10
MA26845A1 (fr) 2004-12-20
HUP0203521A2 (hu) 2003-02-28
PA8506301A1 (es) 2002-08-26
TNSN00231A1 (fr) 2002-05-30
KR20020058057A (ko) 2002-07-12
PL355892A1 (en) 2004-05-31
OA12099A (en) 2006-05-04
WO2001040190A1 (en) 2001-06-07
NO20022558L (no) 2002-05-29
TR200201446T2 (tr) 2002-11-21
EP1246804A1 (en) 2002-10-09
NO20022558D0 (no) 2002-05-29
AP2002002531A0 (en) 2002-06-30
UY26454A1 (es) 2001-07-31
MXPA02005354A (es) 2002-12-11
BG106854A (bg) 2002-12-29
EA200200510A1 (ru) 2002-10-31
AU1048801A (en) 2001-06-12
CA2392979A1 (en) 2001-06-07
PE20010904A1 (es) 2001-09-10
BR0015836A (pt) 2002-08-06
CN1402711A (zh) 2003-03-12
IS6338A (is) 2002-04-12
ECSP003792A (es) 2002-04-23

Similar Documents

Publication Publication Date Title
EE200100166A (et) 4-karboksüamino-2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid
NO20022558D0 (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
EE200100167A (et) 4-amino-asendatud 2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
NO20013003D0 (no) Kinolin-derivater
ATE228505T1 (de) Chinolinderivate
IS5775A (is) Quinoline afleiður
DK1114033T3 (da) 4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoliner som CETP-inhibitorer
NO20016319L (no) VLA-4 inhibitor-forbindelser
NO20006039L (no) Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin
ATE229005T1 (de) Chinolinderivate
CY2009001I2 (el) Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
EE200100039A (et) Ftalasiinderivaadid kui fosfodiesteraas-4 inhibiitorid
NO20023013D0 (no) Substituerte 8-arylkinolinfosfodiesterase-4-inhibitorer
EE200300266A (et) Asendatud 8-arüülkinoliinid kui fosfodiesteraas-4inhibiitorid
NO20022564D0 (no) Nye androgener
DE60107074D1 (de) Kristallin form ii von cabergolin
ATE339438T1 (de) Substanziell kristalline form von melagatran
IL143779A0 (en) Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation
DE69908951D1 (de) Kristallformen von osanetant
DE60026931D1 (de) Ausrichtung von Ausdrucken
NO20013407D0 (no) Fremgangsmåte for fremstilling av kinolinkarbaldehyd
DE50003014D1 (de) N-substituierte perhydrodiazine
DK1224179T3 (da) Natrium-hydrogen-udbytter type 1-inhibitorkrystaller
DE60038936D1 (de) Einkristallziehvorrichtung